Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vânia Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Martínez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E. Gatt, Albert Oriol Rocafiguera, Michèle Cavo, Robert M. Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Shing Yip Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalińska, María-Victoria Mateos (2025). Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. , 26(8), DOI: https://doi.org/10.1016/s1470-2045(25)00330-4.
